Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly